Neoxantina

Otros Nombres

(3S,3′S,5R,5′R,6R,6′S)-6,7-didehydro-5′,6′-epoxy-5,6,5′,6′-tetrahydro-β,β-carotene-3,5,3′-triol(3S,3′S,5R,5′R,6R,6′S,9′-cis)-6,7-Didehydro-5,5′,6,6′-tetrahydro-5′,6′-epoxy-β,β-carotene-3,3′,5-triol(3S,3′S,5R,5′R,6′S)-6,7-Didehydro-5,5′,6,6′-tetrahydro-5′,6′-epoxy-β,β-carotene-3,3′,5-triol(3S,3′S,5R,5′R,6′S,9′cis)-6,7-Didehydro-5,5′,6,6′-tetrahydro-5′,6′-epoxy-β,β-carotene-3,3′,5-triol(3S,5R,6R,3′S,5′R,6′S)-5′,6′-EPOXY-6,7-DIDEHYDRO-5,6,5′,6′-TETRAHYDRO-β,β-CAROTENE-3,5,3′-TRIOL(3S,5R,6R,3′S,5′R,6′S)-6,7-didehydro-5,6,5′,6′-tetrahydro-5′,6′-epoxy-β,β-carotene-3,5,3′-triol(9′Z,3S,5R,6R,3′S,5′R,6′S)-5′,6′-Epoxy-6,7-didehydro-5,6,5′,6′-tetrahydro-β,β-carotene-3,5,3′-triol9'-cis-Neoxanthinall-trans-Neoxanthinallenic xanthophyllcis-NeoxanthinNeoxanthinetrans-Neoxanthinβ,β-Carotene, 6,7-didehydro-5′,6′-epoxy-5,5′,6,6′-tetrahydro-3,3′,5-trihydroxy-, (3S,3′S,5R,5′R,6R,6′S,9′-cis)-β,β-Carotene-3,3′,5-triol, 6,7-didehydro-5′,6′-epoxy-5,5′,6,6′-tetrahydro-, (3S,3′S,5R,5′R,6′S)-

Sinopsis

Neoxanthin: A Comprehensive Reference

1. Identity and Chemical Characterization

Nomenclature and Synonyms

Neoxanthin is a carotenoid and xanthophyll. Its IUPAC chemical name is (3S,3′S,5R,5′R,6R,6′S,9′-cis)-6,7-Didehydro-5′,6′-epoxy-5′,6′-dihydro-β,β-carotene-3,3′,5(6H)-triol. Additional synonyms include 9′-cis-Neoxanthin, cis-Neoxanthin, Foliaxanthin, and Trolliflor. Its CAS Registry Number is 14660-91-4, and its molecular formula is C₄₀H₅₆O₄ with a molecular weight of 600.87 Da.

Structural Features

Neoxanthin, a precursor of the plant hormone abscisic acid, is an allenic xanthophyll recognized as the last product of carotenoid synthesis in green plants. The allenic designation refers to the cumulated diene (allene) moiety within its structure. Violaxanthin is converted to neoxanthin by opening of the cyclohexenyl 5–6-epoxide ring, forming an allenic double bond. Neoxanthin is often present in two forms: all-trans and 9-cis isomers. The most abundant neoxanthin isomer found in chloroplasts is 9′-cis-neoxanthin. As a xanthophyll (oxygenated carotenoid), neoxanthin carries four oxygen atoms incorporated as hydroxyl and epoxide functional groups within its C40 polyene backbone.

Physical Properties and Appearance

Neoxanthin, characterized by its yellow color, is a natural component of vegetable leaves. Like other carotenoids, it is lipophilic and practically insoluble in water. In research settings, neoxanthin is typically dissolved in organic solvents such as ethanol or DMSO for experimental use, and analytical standards are available with ≥90% purity as determined by HPLC. The compound is sensitive to light and oxygen and requires storage at low temperatures, protected from light, and ideally under an inert atmosphere.

2. Natural Sources and Distribution

Higher Plants

Neoxanthin is an allenic xanthophyll and one of the major carotenoids found in plants such as spinach and barley leaves. A trace amount of this pigment is also found in olive oil. Neoxanthin is found in apple and is a constituent of paprika, lucerne (alfalfa), orange, and other species. It is a major xanthophyll found in green leafy vegetables such as spinach. The discovery of neoxanthin dates to the early twentieth century: the study of neoxanthin has a history of around 100 years. The earliest report was in 1938, when Professor Strain first discovered the presence of neoxanthin and named it, identifying it as a common carotenoid distributed in barley leaves.

All xanthophylls synthesized by higher plants — including violaxanthin, antheraxanthin, zeaxanthin, neoxanthin, and lutein — can also be synthesized by green algae. In plants, carotenoid levels can vary by 20–30% depending on the season, and neoxanthin typically accounts for only 9 to 14% of total xanthophylls.

Microalgae

Neoxanthin, a pigment in spinach, is also available in microalgae. The antioxidative property of neoxanthin has been reported in Scenedesmus sp., Chlorella sp., and Tetraselmis suecica. Neoxanthin can also be isolated from Chlorella vulgaris, C. protothecoides, Ankistrodesmus gracilis, Scenedesmus quadricauda, Neochloris oleoabundans, Chlorella pyrenoidosa, Botryococcus braunii, and Nephroselmis pyriformis. Microalgae represent a particularly rich potential commercial source: among published reports, the highest recorded neoxanthin content in the microalga Chlorella vulgaris is 30,880 μg/g dry weight.

The marine green microalga Tetraselmis suecica contains high levels of carotenoids including the xanthophylls lutein, violaxanthin, neoxanthin, antheraxanthin, and loroxanthin esters. Neoxanthin has also been identified in Tetraselmis suecica extracts used in antioxidant and cancer research.

Extraction Challenges and Production Platforms

The extraction of neoxanthin from plant sources presents several challenges: low natural abundance requiring large amounts of biomass, seasonal variability affecting carotenoid content and yield consistency, high resource and labor demands for plant cultivation and harvesting, and extraction methods that often rely on organic solvents, raising environmental and safety concerns. These limitations compromise scalability, cost-effectiveness, and sustainability. As a result, microbial hosts, particularly Saccharomyces cerevisiae, represent a promising platform for the biosynthesis of neoxanthin, enabling controlled, reproducible, and season-independent production, thus providing a more stable and efficient alternative to traditional extraction methods. The bioproduction of neoxanthin by microalgae is also considered a sustainable and promising option.

3. Biosynthesis and Plant Biology

Biosynthetic Pathway

Neoxanthin, a precursor of the plant hormone abscisic acid, is an allenic xanthophyll recognized as the last product of carotenoid synthesis in green plants. It is biosynthesized from violaxanthin via the enzyme neoxanthin synthase (NSY). A cDNA for neoxanthin synthase was isolated from tomato using a molecular approach based on the mechanistic and structural similarities of NSY to two other closely related carotenogenic enzymes, lycopene cyclase (LCY) and capsanthin-capsorubin synthase (CCS). The identified tomato NSY cDNA encodes a 56-kDa plastid-targeted protein that, when expressed in Escherichia coli, catalyzes the conversion of violaxanthin to neoxanthin.

Neoxanthin is produced from violaxanthin, but a suspected neoxanthin synthase is still to be confirmed definitively. Two different genes were confirmed to be involved in violaxanthin conversion to neoxanthin in Arabidopsis and tomato. Only parasitic plants belonging to the Cuscutaceae are known to lack neoxanthin.

Role in Abscisic Acid Biosynthesis

Neoxanthin and violaxanthin can be isomerized from their all-trans to 9′/9-cis forms respectively, and subsequent cleavage of a specific double bond in their polyene backbones by carotenoid cleavage dioxygenases (CCDs) produces xanthoxin, the precursor of the important apocarotenoid phytohormone abscisic acid (ABA). The gene encoding 9-cis-epoxycarotenoid dioxygenase (NCED) was identified in maize as the vp14 gene in 1997, and the encoded enzyme was shown to catalyze oxidative cleavage of 9-cis-neoxanthin.

Photoprotective Role

Neoxanthin has a specific role in protection against photooxidative stress in plants. Neoxanthin, found in plants and algae in two different isomeric forms, is involved in the light stress response at different levels. This xanthophyll is not directly involved in xanthophyll cycles (XCs), and the molecular mechanisms behind its photoprotective activity are yet to be fully resolved. Experimental evidence has shown that xanthophylls — including zeaxanthin, lutein, and neoxanthin — can be responsible for photoprotection in the form of general antioxidant activity.

4. Traditional and Historical Use

Neoxanthin is not a traditional herbal medicine or isolated botanical remedy in the strict ethnobotanical sense. It is a naturally occurring pigment constituent of widely consumed green vegetables that have themselves been part of human diets across numerous cultures for millennia. As an isolated, characterized compound, it was only first scientifically described and named in 1938. No pre-modern traditional medicine system — including Ayurveda, Traditional Chinese Medicine, or European herbalism — referenced neoxanthin as a discrete substance, as the analytic chemistry necessary for its identification did not exist in those eras.

The dietary traditions that most likely provided regular neoxanthin exposure include those of cultures with high consumption of dark leafy greens such as spinach, various brassicas, and other green vegetables. Scientific investigation into neoxanthin as a distinct phytochemical with possible health implications began largely in the late twentieth and early twenty-first centuries, emerging from broader research interest in carotenoids as a class of bioactive dietary compounds.

5. Key Constituents, Active Compounds, and Mechanisms of Action

Antioxidant Mechanisms

Neoxanthin has demonstrated good anti-oxidant activity in various assessments of in vitro antioxidant activity. The antioxidant capacity of neoxanthin is attributed to its extended polyene chain and allenic functional group, features shared with similarly structured xanthophylls such as fucoxanthin. Oxidative stress is implicated in the pathogenesis of diverse disorders, including cancer, inflammatory and hyperpigmentation disorders, neurodegenerative diseases, diabetes, and cardiovascular diseases. This shared biochemical mechanism suggests neoxanthin is a promising candidate compound for the prevention and/or treatment of the coexistence of these multiple diseases.

Pro-Apoptotic and Antiproliferative Mechanisms

Neoxanthin treatment causes an enhancement in the activities of caspase-3, -8, and -9, as well as an increase in the protein levels of their active subunits. In addition, the treatment results in an early-stage reduction in mitochondrial transmembrane potential, followed by the subsequent release of cytochrome c and apoptosis-inducing factor (AIF) from the mitochondria. These events are hallmarks of the intrinsic (mitochondrial) apoptosis pathway. Additionally, the ratio of apoptotic cells reached more than 30% after treatment for 48 h with 20 μM of neoxanthin or fucoxanthin. The carotenoids reduced the expression of Bax and Bcl-2 proteins, but not Bcl-X(L).

Anti-Obesity and Lipid Metabolism Effects

Neoxanthin exhibits anti-obesity, anti-cancer, and anti-inflammatory activities. At the cellular and animal level, neoxanthin has been reported to influence adipogenesis and lipid accumulation, though the precise molecular targets are not yet fully characterized. Neoxanthin contained in young leafy vegetables including spinach has shown a fat accumulation inhibitory effect in vitro.

Anti-Inflammatory Mechanisms

A few xanthophylls, namely astaxanthin, β-cryptoxanthin, lutein, and neoxanthin, have displayed alleviation of inflammatory status, triglyceride levels, as well as liver function, and such xanthophylls showed great potential in anti-cancer, anti-diabetic, and anti-obesity properties. In preclinical models, neoxanthin was found to inhibit chronic renal failure-caused renal aging, fibrosis, oxidative stress, and inflammation.

Glucocorticoid Receptor Modulation

Research has investigated whether xanthophylls and carotenes act as antagonists of the glucocorticoid receptor (GR). The effects of neoxanthin, fucoxanthin, astaxanthin, beta-carotene, isofucoxanthin, and lutein were assessed using an engineered cell line (UAS-bla HEK 293T) expressing GR, tested via the SelectScreen® Cell-Based Nuclear Receptor Profiling Service. Neoxanthin was tested against the agonist dexamethasone. Neoxanthin's inhibitory action starts between 0.1 and 0.3 μM and is above 85% at 10 μM, indicating meaningful GR antagonism at relatively low concentrations in vitro.

Gastrointestinal Metabolism and Metabolites

Two hours following oral administration of neoxanthin at a dosage of 40 nmol per mouse, both neoxanthin and (R/S)-neochrome are detected in the plasma and liver tissues of mice. The concentrations of neoxanthin, (8R)-neochrome, and (8S)-neochrome are approximately 13.6, 10.3, and 11.3 nmol/L in plasma, and 7.3, 10.4, and 6.9 pmol/g in liver, respectively. Additionally, (R/S)-neochrome is identified in the small intestinal contents of mice administered with neoxanthin. Similarly to fucoxanthin, the bioavailability of neoxanthin is low. This may be attributable to the similarity in chemical structures of the two compounds. Currently, the metabolites of neoxanthin are not yet well characterized.

6. Scientific Evidence by Area of Use

6.1 Anticancer Activity

Prostate Cancer (In Vitro)

The most extensively studied anticancer application of neoxanthin is its activity against prostate cancer cells. A landmark study published in the Journal of Nutrition (2001) by Kotake-Nara and colleagues evaluated the effects of 15 different carotenoids on three human prostate cancer cell lines. The effects of 15 kinds of carotenoids on the viability of three lines of human prostate cancer cells — PC-3, DU 145, and LNCaP — were evaluated. When the prostate cancer cells were cultured in a carotenoid-supplemented medium for 72 h at 20 μmol/L, 5,6-monoepoxy carotenoids, namely, neoxanthin from spinach and fucoxanthin from brown algae, significantly reduced cell viability to 10.9 and 14.9% for PC-3, 15.0 and 5.0% for DU 145, and nearly zero and 9.8% for LNCaP, respectively. DNA fragmentation of nuclei in neoxanthin- and fucoxanthin-treated cells was detected by in situ TUNEL assay. Neoxanthin and fucoxanthin were found to reduce cell viability through apoptosis induction in the human prostate cancer cells. These results suggest that ingestion of leafy green vegetables and edible brown algae rich in neoxanthin and fucoxanthin might have the potential to reduce the risk of prostate cancer.

A subsequent 2005 study specifically examined the apoptotic mechanism in PC-3 cells. The ratio of apoptotic cells reached more than 30% after treatment for 48 h with 20 μM of the carotenoids. The cells reduced expression of Bax and Bcl-2 proteins, but not Bcl-X(L). Fucoxanthin accumulated in the cells at the same level as neoxanthin.

Strength of evidence: These studies are purely in vitro (cell culture). No animal studies or human clinical trials have specifically evaluated neoxanthin's efficacy in prostate cancer, and the results cannot be directly extrapolated to in vivo scenarios, particularly given the documented low bioavailability of neoxanthin in humans (discussed below).

Colon Cancer (In Vitro)

The effects of 9′-cis-neoxanthin on the induction of apoptosis in HCT116 human colon cancer cells have been assessed, and the underlying mechanisms for its anti-cancer effects have been elucidated. The results have shown that chromatin condensation, DNA fragmentation, and increased hypodiploid cells were observed when HCT116 human colon cancer cells were exposed to 20 μM neoxanthin. In addition, treatment with neoxanthin at 5 μM significantly inhibits the proliferation of HCT116 cells.

Strength of evidence: In vitro only. No human data. The same bioavailability caveats apply.

Cervical and Lung Cancer (In Vitro)

Neoxanthin, a xanthophyll carotenoid isolated from T. suecica, demonstrated remarkable cytotoxicity towards tumor cells. Of four xanthophylls tested, 9-Z-neoxanthin showed the highest efficacy in reducing the viability of cervical HeLa cells (IC₅₀ = 3.8 μM) and lung A549 cells (IC₅₀ = 7.5 μM).

Strength of evidence: In vitro only. Preliminary. The relatively low IC₅₀ values are notable but do not translate directly to clinical relevance without bioavailability and pharmacokinetic data in humans.

6.2 Antioxidant Activity

Neoxanthin, a pigment in spinach, is also available in microalgae. Its antioxidative property has been reported in Scenedesmus sp., Chlorella sp., and Tetraselmis suecica. A study on a Tetraselmis suecica extract rich in neoxanthin demonstrated that the extract has strong antioxidant and repairing activity in the human lung cancer cell line (A549), as shown by the increased expression of dehydrocholesterol reductase-24 (DHCR24) and prostaglandin reductase 1 (PTGR1) genes and proteins. However, this study used a multi-component algal extract rather than purified neoxanthin, so specific attribution of effects to neoxanthin alone is not possible.

Strength of evidence: Primarily in vitro. The antioxidant capacity of neoxanthin in isolation has been demonstrated across several laboratory assays, but no controlled human studies have measured its in vivo antioxidant effects specifically.

6.3 Anti-Obesity and Metabolic Effects

In a previous study, the carotenoid neoxanthin was contained in young leafy vegetables including spinach and showed a fat accumulation inhibitory effect in vitro. To evaluate the bioavailability of neoxanthin, a raw young spinach leaf (100 g day⁻¹ for 4 weeks) intake test was performed on 14 participants (mean age 36.5 ± 8.0 years; male:female ratio = 9:5). Neoxanthin, neochrome, β-carotene, and lutein concentrations in the spinach and blood of participants (before and after the test) were measured using high-performance liquid chromatography. Neither neoxanthin nor neochrome was detected in the blood samples, whereas β-carotene and lutein concentrations significantly increased (1.4- and 1.9-fold, respectively) during testing. Neoxanthin bioavailability in humans is low; thus, it is unlikely to have a fat accumulation inhibitory effect in vivo, contrary to the result in vitro.

Strength of evidence: The only published human study on neoxanthin's anti-obesity potential demonstrated that neoxanthin from raw spinach is not detectably absorbed into the bloodstream. This is a critically important negative finding that casts doubt on the translational relevance of favorable in vitro and animal data. The human study was small (14 participants) and did not use isolated neoxanthin as a supplement.

6.4 Renal Protection (Anti-Aging and Anti-Fibrotic Effects)

The potential therapeutic effects of neoxanthin on chronic renal failure (CRF)-caused aging and fibrosis were investigated using biochemistry, immunohistochemistry, and molecular biology techniques. In vitro, neoxanthin alleviated the aging and oxidative damage of kidney cells. In vivo (animal model), neoxanthin was found to alleviate adenine-induced CRF. Neoxanthin also inhibited CRF-caused renal aging, fibrosis, oxidative stress, and inflammation.

Strength of evidence: Preclinical only (in vitro and animal model). No human trials have evaluated neoxanthin for kidney disease. Results are exploratory and hypothesis-generating.

6.5 Dietary Carotenoid Intake and Breast Cancer Risk (Epidemiological)

A population-based case-control study recruited 600 patients with newly diagnosed breast cancer and 600 healthy controls. Dietary carotenoid intake was assessed using a validated 168-item food frequency questionnaire. The intake levels of α-carotene, β-carotene, β-cryptoxanthin, lutein/zeaxanthin, lycopene, astaxanthin, phytoene, phytofluene, neoxanthin, violaxanthin, and total carotenoids were categorized into quartiles. While this epidemiological study included neoxanthin among the carotenoids assessed, it measured dietary intake of neoxanthin through food sources rather than supplementation, and the independent contribution of neoxanthin as a single compound cannot be disentangled from total dietary patterns.

Strength of evidence: Epidemiological; association data only. Neoxanthin was included as one of many dietary variables, and no causative link to breast cancer risk can be attributed specifically to neoxanthin from this study design.

7. Body Systems and Health Areas of Association

Oncology / Cancer Biology: In vitro evidence for apoptosis induction and antiproliferative effects in prostate, colon, cervical, and lung cancer cell lines. No clinical trial data.
Antioxidant Defense: General free radical scavenging demonstrated in multiple in vitro antioxidant assays; potentially relevant to oxidative stress-driven conditions including cardiovascular disease, neurodegeneration, and metabolic disorders.
Metabolic / Adipose Tissue: In vitro fat accumulation inhibition; however, the sole available human bioavailability study failed to detect neoxanthin in blood after dietary spinach ingestion, calling in vivo efficacy into question.
Renal System: Preclinical evidence of protective effects against chronic renal failure-induced aging, oxidative stress, and fibrosis in cellular and animal models.
Endocrine / Glucocorticoid Signaling: In vitro GR antagonism demonstrated in engineered cell lines at concentrations starting between 0.1 and 0.3 μM.
Plant Photosynthesis (Photoprotection): Well-established role in protecting photosynthetic organisms from oxidative photo-damage; not directly a human health mechanism but underpins its ecological prevalence in dietary plants.

8. Dosage Forms and Doses Reported in Studies

Neoxanthin is not currently marketed as an approved dietary supplement with established dosages in the way that lutein or astaxanthin are. The following doses derive exclusively from published research:

In vitro cell studies: Concentrations of 20 μM neoxanthin induced chromatin condensation, DNA fragmentation, and increased hypodiploid cells in HCT116 human colon cancer cells, while 5 μM significantly inhibited their proliferation.
In vitro prostate cancer studies: Prostate cancer cells were cultured in carotenoid-supplemented medium for 72 h at 20 μmol/L.
In vitro HeLa and A549 cancer cells: 9-Z-neoxanthin showed an IC₅₀ of 3.8 μM against cervical HeLa cells and 7.5 μM against lung A549 cells.
In vitro GR antagonism: Neoxanthin inhibitory action against the glucocorticoid receptor starts between 0.1 and 0.3 μM and is above 85% at 10 μM.
Animal pharmacokinetic study: Two hours following the oral administration of neoxanthin at a dosage of 40 nmol per mouse, both neoxanthin and (R/S)-neochrome are detected in the plasma and liver tissues of the mice.
Human dietary intake study: A raw young spinach leaf intake of 100 g day⁻¹ for 4 weeks was administered to 14 human participants. This study did not use isolated neoxanthin supplementation but rather the whole food as a neoxanthin source.

No human clinical trials have established or tested a specific oral supplemental dose of isolated neoxanthin. There is currently no established recommended or therapeutic dose for humans.

9. Safety Considerations and Interactions

Human Bioavailability: A Critical Safety and Efficacy Context

In the only available human study, neither neoxanthin nor neochrome was detected in blood samples after four weeks of raw spinach consumption, whereas β-carotene and lutein concentrations significantly increased. Neoxanthin bioavailability in humans is low; thus, it is unlikely to have a fat accumulation inhibitory effect in vivo, contrary to the result in vitro. Ingesting the leafy vegetables raw can help maintain high neoxanthin levels in the food itself, but it is not beneficial for neoxanthin bioavailability. This finding is significant: it indicates that even consistent consumption of neoxanthin-rich foods does not result in measurable plasma neoxanthin concentrations in humans.

Metabolite Formation

Currently, the metabolites of neoxanthin are not yet well characterized. More studies are required to develop understanding of the metabolites of neoxanthin or advance neoxanthin as a drug precursor to be further activated by in vivo metabolism. The key identified metabolite is neochrome (formed by rearrangement of the allene group), found in the small intestinal contents of neoxanthin-administered mice. The biological significance of neochrome in humans, including any independent pharmacological activity, has not yet been determined.

Regulatory Status

As of the current state of research, neoxanthin has not been evaluated by major regulatory bodies — including the EFSA Panel on Nutrition, Novel Foods and Food Allergens, the U.S. FDA, or other national food safety authorities — as a specific novel food ingredient or dietary supplement at isolated dosages. No approved maximum levels, acceptable daily intakes (ADIs), or safety assessments analogous to those conducted for carotenoids such as astaxanthin or lutein have been published for neoxanthin specifically.

Absence of Human Toxicology Data

No published human toxicology studies, tolerability studies, or adverse event reports for isolated neoxanthin supplementation exist in the peer-reviewed literature. While the compound is ingested as a natural constituent of commonly consumed vegetables — suggesting general food-level safety — no data support conclusions about the safety of concentrated supplemental doses in humans.

Interactions

No documented drug–nutrient interactions with neoxanthin have been identified in the peer-reviewed literature. Given its in vitro activity as a glucocorticoid receptor antagonist — with inhibitory action starting between 0.1 and 0.3 μM and exceeding 85% at 10 μM — theoretical concerns about interactions with glucocorticoid-based medications exist, but this has not been studied in vivo in humans or animals. The lipophilic nature of neoxanthin suggests it may share absorption-level interactions with other fat-soluble nutrients (e.g., competing with other carotenoids for micellar incorporation), as is known for carotenoids generally, but specific data for neoxanthin are absent.

Storage and Stability

Neoxanthin is sensitive to light, heat, and oxygen, all of which can cause isomerization or oxidative degradation. Analytical-grade reference material is stored at −20°C or below, protected from light, and ideally under nitrogen. These stability concerns are relevant to any food or supplement application, where degradation during processing or storage would reduce or eliminate the neoxanthin content of any preparation.

10. Current Research Landscape and Future Directions

Neoxanthin is a xanthophyll carotenoid with high-value nutritional functions for human health due to its anti-cancer, anti-oxidative, and anti-obesity activities. However, the totality of evidence for these activities remains at a very early stage. The establishment of purification technology can provide necessary high-purity neoxanthin for further studies of the biological activity of neoxanthin. Researchers have noted that further studies are needed to validate the anti-oxidant properties of neoxanthin using multiple in vivo and in vitro models, and the anti-oxidant mechanisms require further determination for its future application in the food industry.

More studies are required to develop the metabolites of neoxanthin or advance neoxanthin as a drug precursor to be further activated by in vivo metabolism. The question of how to overcome its low oral bioavailability — whether through nano-encapsulation, lipid co-administration, structural modification, or metabolic engineering of higher-yielding production strains — represents a central challenge for the field. Microbial hosts, particularly Saccharomyces cerevisiae, represent a promising platform for the biosynthesis of neoxanthin, enabling controlled, reproducible, and season-independent production.

In summary, neoxanthin is a chemically well-characterized natural xanthophyll with a growing body of preclinical evidence suggesting anticancer, antioxidant, anti-inflammatory, and anti-obesity properties. Its documented low bioavailability in humans from dietary sources is a significant translational barrier. No human clinical trials investigating neoxanthin as a therapeutic or supplemental agent have been published to date, and the compound lacks regulatory approval or established dosing guidelines as an isolated supplement.

References

Condiciones de Salud

Condiciones de salud que Neoxantina puede ayudar a apoyar.

No hay condiciones disponibles.

Sistemas Corporales

Sistemas corporales que Neoxantina puede ayudar a apoyar.

No hay sistemas corporales disponibles.